Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company <li /> Nutriband's recent 25% preferred sto ...

Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that primary analysis of the ...

Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resilience PDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

The test, developed in part by Johns Hopkins researchers, will dramatically increase access to early detection and treatment ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

A new nuclear magnetic resonance method reveals real-time, coordinated changes in nanoemulsion drugs, improving noninvasive ...

Extensively studied over decades, fluoride has been scientifically validated for its effectiveness in reducing dental ...

Insightec, the Miami-based innovator in focused ultrasound to transform patient care, announced July 8 the U.S. Food and Drug ...